Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain
NCT ID: NCT03246971
Last Updated: 2018-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
125 participants
INTERVENTIONAL
2017-08-24
2018-07-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy
NCT02541396
Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients
NCT03599089
Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy
NCT00656578
A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
NCT06619847
A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy
NCT02077140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wafermine™
Wafermine™ 50 mg
Administered as needed for 12 hours
Wafermine™ 75 mg
Administered as needed for 12 hours
Wafermine™ 25 mg
Administered as needed for 12 hours
Placebo
Placebos
Administered as needed for 12 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Wafermine™ 50 mg
Administered as needed for 12 hours
Wafermine™ 75 mg
Administered as needed for 12 hours
Placebos
Administered as needed for 12 hours
Wafermine™ 25 mg
Administered as needed for 12 hours
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Good general health without clinically significant renal, hepatic, cardiac or respiratory disease, as determined by the Investigator.
Exclusion Criteria
* Positive lab values for Hepatitis B or C or HIV
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
iX Biopharma Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lotus Clinical Research
Pasadena, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KET010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.